Organ transplantation

A Visionary Embracing the Mission: Welcoming Eric Williams to HDM's Board of Directors

Retrieved on: 
Friday, February 2, 2024
COVID-19, Administration, American College, Knowledge, Patient satisfaction, HDM, University, Health, Patient, Public health, Health care, Pennsylvania State University, Organ transplantation, Stanford University Medical Center, Health policy, Kaiser Permanente, Management

NEW YORK, Feb. 2, 2024 /PRNewswire-PRWeb/ -- Health Data Movers (HDM), a leading healthcare technology services firm, welcomes Eric Williams to the company's Board of Directors. Williams is the senior vice president and area manager for the Kaiser Permanente Santa Clara Service area. With his years of experience and knowledge of the healthcare landscape, Eric Williams's addition to the Board of Directors will further empower HDM to achieve its mission of empowering patients and providers through technology.

Key Points: 
  • NEW YORK, Feb. 2, 2024 /PRNewswire-PRWeb/ -- Health Data Movers (HDM), a leading healthcare technology services firm, welcomes Eric Williams to the company's Board of Directors.
  • Williams is the senior vice president and area manager for the Kaiser Permanente Santa Clara Service area.
  • "I'm delighted to join Health Data Movers' Board of Directors to build upon HDM's current success and shape its inspiring future.
  • We HDMers are fortunate to have Eric with us in our pursuit of becoming healthcare's most respected technology services firm."

Valeos Welcomes Strategic Board Members and Advisors

Retrieved on: 
Wednesday, January 31, 2024
Quality of life, Former, Organ transplantation, Transplant, Human services, Family, History, Disability discrimination act, HHS, Advisory Committee, Entrepreneurship, Federation, CPO, Electronic health record, American Express, Representative, Organ, Privacy, Government, Marketing, SVP, White, Whip (politics), HIPAA, Risk management, Health information management, House, CISO, Sivak, Information technology, Conference

WASHINGTON, Jan. 31, 2024 /PRNewswire/ -- Valeos, a newly formed 501(c)(3) nonprofit organization designed to radically improve organ transplant outcomes through shared data, today announced the first appointments to its Board of Directors and Advisory Committee. The strategic coalition of leaders—spanning healthcare, technology and government—share a commitment to saving and extending lives through organ transplantation by championing data utilization, standardizing high-quality care and advocating for equity and accessibility.

Key Points: 
  • Members of the Valeos Board of Directors and Advisory Committee include:
    Stephanie Trunzo, SVP & GM at Oracle Heath.
  • Valeos founders Tristan and Jordan Mace will serve as Co-Chairs of the Board of Directors.
  • More board members and advisors for Valeos are to come in Q1 2024.
  • Jordan and I have since dedicated our lives to advancing organ transplant outcomes through shared data, leading to the creation of Valeos," said Tristan Mace, Co-Founder and Executive Chairman of Valeos.

National Kidney Foundation Innovation Fund Invests in ImmunoFree

Retrieved on: 
Tuesday, January 30, 2024
National Kidney Foundation, Growth, Immunosuppression, Research, Patient, Kidney disease, Kidney, Transplant, Longevity, COVID, National Kidney Registry, Quality of life, Risk, Dialysis, Kidney transplantation, Organ transplantation, Health equity, Health, NKF, Cancer, Dentistry

NEW YORK, Jan. 30, 2024 /PRNewswire/ -- The National Kidney Foundation (NKF) announced today its latest strategic investment through its NKF Innovation Fund. The fund will support ImmunoFree, a pioneering biomedical company dedicated to reshaping the landscape of organ transplantation by eliminating the need for immunosuppressive medications.

Key Points: 
  • ~
    NEW YORK, Jan. 30, 2024 /PRNewswire/ -- The National Kidney Foundation (NKF) announced today its latest strategic investment through its NKF Innovation Fund.
  • "In a post COVID world, solving the issues raised by immunosuppressive medications for transplant patients has never been more critical," said Kevin Longino, CEO of the National Kidney Foundation and a kidney transplant recipient.
  • Launched in 2021, the NKF Innovation Fund works to accelerate funding, development, and commercialization of therapies that kidney patients need and deserve.
  • The fund invests in early to mid-stage companies that are developing innovative, patient-centric kidney therapies.

KFSH&RC-Madinah Receives Prestigious 2023 Press Ganey Human Experience Guardian of Excellence Award

Retrieved on: 
Monday, January 29, 2024
Organ transplantation, Patient, Newsweek, KFSH, History, Genetics, GM, Neuroscience, Cancer, Safety, Health, RC, Nursing

RIYADH, Saudi Arabia, Jan. 29, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSH&RC) in Madinah has won the 2023 Human Experience Guardian of Excellence Award by Press Ganey for its exceptional performance in outpatient services throughout the past year. This prestigious recognition honored a distinguished group of healthcare institutions, from approximately 1500 facilities globally, for being amongst the top 5% performers in patient experience in one year.

Key Points: 
  • RIYADH, Saudi Arabia, Jan. 29, 2024 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSH&RC) in Madinah has won the 2023 Human Experience Guardian of Excellence Award by Press Ganey for its exceptional performance in outpatient services throughout the past year.
  • This prestigious recognition honored a distinguished group of healthcare institutions, from approximately 1500 facilities globally, for being amongst the top 5% performers in patient experience in one year.
  • Through this award, Press Ganey, a leading global organization in measuring and enhancing patient experience, reflects KFSH&RC's commitment to delivering top-tier healthcare solutions and outstanding patient experiences across various healthcare services within an integrated education and research setting.
  • The 2023 Press Ganey Award ceremony is set to be announced later in February.

3D Bio-Printing Industry to Surpass a Valuation of US$ 6.82 billion By 2034. Players to Capitalize on the Rising Demand for 3D Bio-printing during the Forecast Period

Retrieved on: 
Wednesday, January 24, 2024
Organ transplantation, Regenerative medicine, Patient, Research, Associate, Injury, Material, Tissue, 3D bioprinting, Risk, Quality of life, Investment, Tissue engineering, 3D, Printing, Transplant, Biomaterial, FMI, Elasticity, Growth, 3D printing

NEWARK, Del., Jan. 24, 2024 /PRNewswire/ -- The global 3D Bio-Printing Market is expected to grow at an exponential CAGR of 11.8% between 2024 and 2034, to reach US$ 2.24 billion in 2024 and US$ 6.82 billion by 2034. The desire for customized medicine, growing investments in bio printing technology, partnerships between biotech firms, healthcare providers, and research institutes, as well as advancements in tissue engineering and regenerative medicine, are driving the growth of the worldwide 3D bio-printing demand.

Key Points: 
  • This development has significantly enhanced the accuracy and functionality of 3D printed structures, making them more suitable for biomedical applications.
  • The growing demand for 3D bio-printing is a significant trend driven by the need for personalized medicine .
  • Collaborations with academic institutes and healthcare organizations promote a multidisciplinary approach, hastening the translation of 3D bio-printing into therapeutic applications.
  • Market players are always exploring new materials to enhance the biocompatibility and structural integrity of printed tissues, such as bio-inks and biomimetic compounds.

3D Bio-Printing Industry to Surpass a Valuation of US$ 6.82 billion By 2034. Players to Capitalize on the Rising Demand for 3D Bio-printing during the Forecast Period

Retrieved on: 
Wednesday, January 24, 2024
Organ transplantation, Regenerative medicine, Patient, Research, Associate, Injury, Material, Tissue, 3D bioprinting, Risk, Quality of life, Investment, Tissue engineering, 3D, Printing, Transplant, Biomaterial, FMI, Elasticity, Growth, 3D printing

NEWARK, Del., Jan. 24, 2024 /PRNewswire/ -- The global 3D Bio-Printing Market is expected to grow at an exponential CAGR of 11.8% between 2024 and 2034, to reach US$ 2.24 billion in 2024 and US$ 6.82 billion by 2034. The desire for customized medicine, growing investments in bio printing technology, partnerships between biotech firms, healthcare providers, and research institutes, as well as advancements in tissue engineering and regenerative medicine, are driving the growth of the worldwide 3D bio-printing demand.

Key Points: 
  • This development has significantly enhanced the accuracy and functionality of 3D printed structures, making them more suitable for biomedical applications.
  • The growing demand for 3D bio-printing is a significant trend driven by the need for personalized medicine .
  • Collaborations with academic institutes and healthcare organizations promote a multidisciplinary approach, hastening the translation of 3D bio-printing into therapeutic applications.
  • Market players are always exploring new materials to enhance the biocompatibility and structural integrity of printed tissues, such as bio-inks and biomimetic compounds.

AHN Allegheny General Hospital Achieves Prestigious Magnet® Designation for Nursing Excellence

Retrieved on: 
Friday, January 19, 2024
Magnet, AHN, Organ transplantation, General Hospital, Patient, Commission, Nursing, Allegheny General Hospital, Professional, Hospital, Trauma, MD, RN, BSN, Health, Culture, Medicine, Neuroscience, AGH, Allegheny Health Network, Doctor of Philosophy, Organization, MPM, ANCC, Research

PITTSBURGH, Jan. 19, 2024 /PRNewswire-PRWeb/ -- Allegheny General Hospital (AGH), part of the Allegheny Health Network (AHN), has achieved Magnet® designation, a prestigious recognition that reflects the hospital's superior levels of nursing professionalism, teamwork, and patient care.

Key Points: 
  • Allegheny General Hospital (AGH), part of the Allegheny Health Network (AHN), has achieved Magnet® designation, a prestigious recognition that reflects the hospital's superior levels of nursing professionalism, teamwork, and patient care.
  • PITTSBURGH, Jan. 19, 2024 /PRNewswire-PRWeb/ -- Allegheny General Hospital (AGH), part of the Allegheny Health Network (AHN), has achieved Magnet® designation, a prestigious recognition that reflects the hospital's superior levels of nursing professionalism, teamwork, and patient care.
  • This Magnet designation is a reflection of the tireless dedication and exceptional nursing skills of our team at Allegheny General Hospital.
  • It is now the fourth AHN hospital to receive the Magnet designation, part of the network's ongoing campaign to transform the practice of nursing and sustain a culture of nursing excellence and innovation.

Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada

Retrieved on: 
Tuesday, January 16, 2024
Organ transplantation, RVV, Research, Nerve, Seizure, Survival, University, NAC, Injury, Inflammation, Neuroprotection, DRDC, Diazepam, Public, Infection, National security, Disorder, FDA, Therapy, Bleeding, Brain, Health Canada, Endocytosis, Pharmaceutical industry

TORONTO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced an update on the Company’s project evaluating Bucillamine as a potential treatment for nerve agent exposure with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence.

Key Points: 
  • TORONTO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced an update on the Company’s project evaluating Bucillamine as a potential treatment for nerve agent exposure with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence.
  • The Company and the DRDC have finalized the research protocol and expect the project to be completed by the end of Q2-2024.
  • DRDC is investigating pharmacological compounds that can mitigate nerve agent induced brain injury.
  • Bucillamine and NAC will be evaluated to determine the effect on GABA(A) receptor endocytosis and the effect on diazepam effectiveness in terminating seizures.

Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine

Retrieved on: 
Wednesday, January 10, 2024
Organ transplantation, RVV, Technology transfer, Research, University, Injury, Inflammation, Public, Infection, National security, Disorder, Solubility, FDA, Therapy, Defense, Inclusion, Trial of the century, Pharmaceutical industry

TORONTO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has completed the formulation development work of the Company’s next-generation lyophilized formulation of Bucillamine (“New Bucillamine”) conducted at the University of Waterloo.

Key Points: 
  • TORONTO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has completed the formulation development work of the Company’s next-generation lyophilized formulation of Bucillamine (“New Bucillamine”) conducted at the University of Waterloo.
  • The New Bucillamine has the potential to unlock the therapeutic utility of Bucillamine for treating public health medical emergencies, including pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks.
  • Key research findings and observations include:
    Lyophilization of Bucillamine enhances solubility 2.7x compared to standard solution of Bucillamine;
    Inclusion of lyophilization in the Bucillamine formulation approach can result in an ability to increase Bucillamine delivery per dosing unit; and
    Inclusion of lyophilization in the Bucillamine formulation approach offers a simple way to create a parenteral injection product with minimal formulation additives.
  • Also, the Company may explore the New Bucillamine as a potent antioxidant and anti-inflammatory, for rare inflammatory disorders such as ischemia-reperfusion injury (i.e.

CareDx Adds to AlloSure Kidney and HeartCare Utility and Clinical Data at 2024 American Society of Transplant Surgeons Winter Symposium

Retrieved on: 
Thursday, January 11, 2024
Medical Supplies, Health, Medical Devices, Health Technology, Other Health, Cardiology, Biotechnology, Patient, MD, ASTS, Organ transplantation, Risk assessment, Distinguishing, Transplant, Annual, Society, Division, Immunosuppression, Caregiver, Risk, Doctor of Philosophy, Dentistry

CareDx and research collaborators are sharing the latest clinical advances to help advance transplant patient care using CareDx’s non-invasive testing services and digital health solutions at the meeting.

Key Points: 
  • CareDx and research collaborators are sharing the latest clinical advances to help advance transplant patient care using CareDx’s non-invasive testing services and digital health solutions at the meeting.
  • “As a longtime supporter of ASTS, we are honored to continue our commitment as the Founder's Circle Sponsor.
  • It is gratifying to witness the clinical use of our non-invasive molecular diagnostics, predictive modeling, and digital health tools make a tangible impact in advancing transplant patient care,” said Robert Woodward, PhD, Chief Scientific Officer at CareDx.
  • The following speakers will also discuss the integration of these technologies into clinical practice and means for future development.